Ischemia-Reperfusion Injury in Lung Transplantation

Lung transplantation has been established worldwide as the last treatment for end-stage respiratory failure. However, ischemia-reperfusion injury (IRI) inevitably occurs after lung transplantation. The most severe form of IRI leads to primary graft failure, which is an important cause of morbidity and mortality after lung transplantation. IRI may also induce rejection, which is the main cause of mortality in recipients. Despite advances in donor management and graft preservation, most donor grafts are still unsuitable for transplantation. Although the pulmonary endothelium is the primary target site of IRI, the pathophysiology of lung IRI remains incompletely understood. It is essential to understand the mechanism of pulmonary IRI to improve the outcomes of lung transplantation. Therefore, we reviewed the state-of-the-art in the management of pulmonary IRI after lung transplantation. Recently, the ex vivo lung perfusion (EVLP) system has been clinically introduced worldwide. Various promising therapeutic strategies for the protection of the endothelium against IRI, including EVLP, inhalation therapy with therapeutic gases and substances, fibrinolytic treatment, and mesenchymal stromal cell therapy, are awaiting clinical application. We herein review the latest advances in the field of pulmonary IRI in lung transplantation.

Automated summary

Lung transplantation is an established treatment for end-stage respiratory failure, but ischemia-reperfusion injury (IRI) remains a significant complication. The pathophysiology of lung IRI is not fully understood, but promising therapeutic strategies such as the ex vivo lung perfusion system are being developed to improve outcomes.